中国医学前沿杂志（电子版）2024，Vol.16Issue(7)：62-68,7.DOI:10.12037/YXQY.2024.07-07
二甲双胍辅助治疗糖尿病合并耐多药结核病的研究进展
Research progress on the adjunctive therapy of metformin in the treatment of diabetes mellitus with multidrug-resistant tuberculosis
摘要
Abstract
Tuberculosis caused by Mycobacterium tuberculosis is a major global infectious disease.Diabetes mellitus can increase the risk of tuberculosis and worsen the treatment outcomes of tuberculosis,and also make mycobacterium tuberculosis more resistant to drugs.The treatment situation for patients with multidrug-resistant tuberculosis and extensively drug-resistant tuberculosis remains severe globally,and there is an urgent need to find new therapies that are effective,safe,and shorten the duration of treatment.Studies have shown that therapeutic modulation of the immune response of tuberculosis patients can promote the elimination of mycobacterium tuberculosis and limit excessive pathological reactions,known as host-directed therapy.Metformin(MET)is a drug approved for the treatment of type 2 diabetes mellitus.Recently,a large number of studies have shown the benefits of MET for tuberculosis patients,which may complement novel therapies for drug-resistant mycobacterium tuberculosis.This article discusses the research progress of metformin as a potential host-directed therapy for the treatment of multidrug-resistant tuberculosis against the backdrop of the co-epidemic of diabetes and tuberculosis.关键词
二甲双胍/结核病/2型糖尿病/药物治疗Key words
Metformin/Tuberculosis/Type 2 diabetes/Medication引用本文复制引用
武卓然,刘荣梅..二甲双胍辅助治疗糖尿病合并耐多药结核病的研究进展[J].中国医学前沿杂志（电子版）,2024,16(7):62-68,7.基金项目
Leading Talents of Beijing Tongzhou District High-level Talents Development Support Program(YHLD2019011) （YHLD2019011）
High-Level Public Health Technical Personnel Construction Project(Backbone of The Discipline-03-049) 北京市通州区高层次人才发展支持计划领军人才(YHLD2019011) （Backbone of The Discipline-03-049）
高层次公共卫生技术人才建设项目(学科骨干-03-049) （学科骨干-03-049）
